Considerations About the risk of Neurovascular Late Effects in Pediatric Radiotherapy

IF 6.4 1区医学 Q1 ONCOLOGY

International Journal of Radiation Oncology Biology Physics Pub Date : 2025-02-03 DOI:10.1016/j.ijrobp.2024.11.028

L. Toussaint , L. Tram Henriksen , K. Van Beek , S. Bolle , C. Demoor-Goldschmidt , J. Gains , M. Høyer , S. Isebaert , G. Janssens , R. Kortmann , C. Martins Pedro , K. Scheinemann , B. Timmermann , Y. Lassen-Ramshad

{"title":"Considerations About the risk of Neurovascular Late Effects in Pediatric Radiotherapy","authors":"L. Toussaint , L. Tram Henriksen , K. Van Beek , S. Bolle , C. Demoor-Goldschmidt , J. Gains , M. Høyer , S. Isebaert , G. Janssens , R. Kortmann , C. Martins Pedro , K. Scheinemann , B. Timmermann , Y. Lassen-Ramshad","doi":"10.1016/j.ijrobp.2024.11.028","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Survivors of pediatric brain tumors are at an increased risk of developing neurovascular disease, with radiotherapy being a major determinant. The aim of this project was to map how the risk of neurovascular late effects is considered when treating pediatric patients with a brain or skull base tumor with radiotherapy.</div></div><div><h3>Methods</h3><div>A web-based survey, prepared in the frame of the HARMONIC project (harmonicproject.eu) together with the SIOPE radiotherapy working group (ROWG) was distributed to ROWG members throughout Europe. The survey included 33 questions about neurovascular structures at risk, screening and information of the patients, recommendations, and follow-up programs.</div></div><div><h3>Results</h3><div>47 participants from 18 European countries completed the survey, with 87% of them treating patients with photon therapy. 39 of the respondents (83%) never delineated specific structures for large vessel disease, mainly because no dose constraints exist (31/39, 79%) and neurovascular structures are not traditionally integrated into pediatric radiotherapy protocols (28/39, 71%). 35 of the respondents (74%) did not screen patients for risk factors of neurovascular disease before radiotherapy. Of the respondents, 22 (47%) informed all patients with a brain or skull base tumor of the risk of large vessel disease after radiotherapy, and 24 (55%) informed all patients of the risk of small vessel disease. 26 (55%) didn't have a follow-up imaging program for neurovascular disease after radiotherapy in pediatric patients, and 32 (68%) didn't have a follow-up program with blood sampling for seromarkers of risks of neurovascular disease. Of note, 94% of the respondents expressed interest in participating in a follow-up workshop on neurovascular disease after radiotherapy in pediatric patients.</div></div><div><h3>Conclusion</h3><div>Despite a general agreement on the importance of this topic, neurovascular late effects are currently not well included in the clinical practice of European radiotherapy centers.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e7"},"PeriodicalIF":6.4000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624036022","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Survivors of pediatric brain tumors are at an increased risk of developing neurovascular disease, with radiotherapy being a major determinant. The aim of this project was to map how the risk of neurovascular late effects is considered when treating pediatric patients with a brain or skull base tumor with radiotherapy.

Methods

A web-based survey, prepared in the frame of the HARMONIC project (harmonicproject.eu) together with the SIOPE radiotherapy working group (ROWG) was distributed to ROWG members throughout Europe. The survey included 33 questions about neurovascular structures at risk, screening and information of the patients, recommendations, and follow-up programs.

Results

47 participants from 18 European countries completed the survey, with 87% of them treating patients with photon therapy. 39 of the respondents (83%) never delineated specific structures for large vessel disease, mainly because no dose constraints exist (31/39, 79%) and neurovascular structures are not traditionally integrated into pediatric radiotherapy protocols (28/39, 71%). 35 of the respondents (74%) did not screen patients for risk factors of neurovascular disease before radiotherapy. Of the respondents, 22 (47%) informed all patients with a brain or skull base tumor of the risk of large vessel disease after radiotherapy, and 24 (55%) informed all patients of the risk of small vessel disease. 26 (55%) didn't have a follow-up imaging program for neurovascular disease after radiotherapy in pediatric patients, and 32 (68%) didn't have a follow-up program with blood sampling for seromarkers of risks of neurovascular disease. Of note, 94% of the respondents expressed interest in participating in a follow-up workshop on neurovascular disease after radiotherapy in pediatric patients.

Conclusion

Despite a general agreement on the importance of this topic, neurovascular late effects are currently not well included in the clinical practice of European radiotherapy centers.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Radiation Oncology Biology Physics 医学-核医学

CiteScore

11.00

自引率

7.10%

发文量

2538

审稿时长

6.6 weeks

期刊介绍： International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.